Healthcare | July 06, 2022
Apollo Hospitals integrates cardiovascular risk tool with ConnectedLife digital wellness solutions
The AICVD tool can predict the risk of cardiovascular disease.
The AICVD tool can predict the risk of cardiovascular disease.
The Cidmus brand shall be affixed on the pharmaceutical composition comprising a combination of Valsartan and Sacubitril (currently under Novartis patent) which is indicated for heart failure patients with reduced ejection fraction
New data, including two late-breaking clinical trial presentations on mavacamten and a new analysis of the GUARD-AF study, reinforce the company’s continued commitment to those living with cardiovascular disease
Cardiovascular disease is the leading cause of death in the Asia Pacific, and it's a problem that will only intensify as populations continue to age
One of the key factors driving the market growth is the rise in the occurrence of chronic cardiovascular diseases such as heart failure and coronary artery disease: Valuates Reports
Zydus MedTech gets rights to market the innovative Transcatheter Aortic Valve Implantation (TAVI) technology in India, Europe and other select markets
Vote expands existing recommendation, which was for all adults aged 75 and older and high-risk adults aged 60 to 74
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
Abbott's investigational Coronary Intravascular Lithotripsy (IVL) System offers a new potential treatment by using sound pressure waves to treat arterial calcium blockages
Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region
Subscribe To Our Newsletter & Stay Updated
